Interview with Louis Chiang, President, Giddi Pharma Co. Ltd.
Giddi Pharma was founded in 1995. What was the vision behind the creation of the company? What founding principles did you have when you founded Giddi? When I founded this…
Address: Avenue Provinciale, 30
1340 Louvain-la-Neuve
Belgium
Tel: +32 (0)10 61 44 44
Web: http://www.iddi.com/
IDDI’s business is that of a eClinical and Biostatistical services provider for clinical trials since 1991. IDDI’s mission is to optimize the clinical development of drugs, biologics and devices, using a unique combination of advanced biostatistics and innovative data management technology.
Services:
Innovative trial design
Biostatistics: expert statistical analyses, validation of biomarkers, support to IDMC
Cost effective Data management and Electronic Data Capture
Professional Medical writing
eClinical Suite
IWRS / IVRS : ID-net™, a centralized randomization system integrated with EDC.
ID-supply™ , a drug inventory and treatment allocation system.
ID-code™, a coding of medical terms system based onMedDRA® and WHO-DRUG dictionaries.TrialControl™, a secure eRoom portal to access to key trial data and documents.
Giddi Pharma was founded in 1995. What was the vision behind the creation of the company? What founding principles did you have when you founded Giddi? When I founded this…
Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
See our Cookie Privacy Policy Here
